[18F]AlF-NOTA-FAPI-04

[18F]AlF-NOTA-FAPI-04 is a novel radiopharmaceutical used as a positron emission tomography (PET) imaging agent. It is designed to target fibroblast activation protein (FAP), which is overexpressed in cancer-associated fibroblasts and in fibrotic diseases. As a FAP inhibitor-based tracer (also known as FAPI), it enables non-invasive visualization of FAP expression in vivo. The compound consists of the small molecule inhibitor FAPI-04 conjugated to the NOTA chelator and labeled with fluorine-18 via an aluminum fluoride complexation strategy. This labeling method allows for high radiochemical yield and purity, enabling large-scale production suitable for clinical use due to the favorable half-life of fluorine-18 compared to gallium-based tracers. [18F]AlF-NOTA-FAPI-04 has demonstrated high tumor uptake and excellent tumor-to-background ratios across various cancers (including breast cancer and pancreatic ductal adenocarcinoma) as well as fibrotic diseases, making it valuable for diagnosis, staging, treatment response prediction, and potentially therapy planning[1][2][3][4][8].

Brand names

NOTA-FAPI04NOTA-FAPI-04NOTA-FAPI 04

Other names

[18F]AlF-NOTA-FAPI-0418F-AlF-NOTA-FAPI-04FAPI-04FAPI04FAPI 04